Concure Oncology revealed on Friday the addition of Scott Armstrong to its board of directors.
As a member of the company's board, Armstrong supports the advancement of Breast Microseed Treatment as well as continue his advocacy for patient-centric care.
Most recently, Armstrong has served as president and CEO of Group Health Cooperative, anot-for-profit health plan company, positions he has held for 12 years.
Previously at Group Health, Armstrong has worked as VP of Network Services, executive VP/chief administrative officer as well as executive VP/chief operating officer.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis